Back to resultsSurvival on Peritoneal Dialysis (PD) Versus Hemodialysis (HD) in China
Primary Purpose
End Stage Renal Disease
Status
Terminated
Phase
Phase 4
Locations
China
Study Type
Interventional
Intervention
Peritoneal Dialysis treatment
Hemodialysis treatment
Sponsored by
About this trial
This is an interventional treatment trial for End Stage Renal Disease focused on measuring End Stage Renal Disease, ESRD, Peritoneal Dialysis, PD, Hemodialysis, HD
Eligibility Criteria
Inclusion Criteria:
- Subjects of either sex, aged 18 years or older at time of randomization.
- Subjects diagnosed with ESRD (glomerular filtration rate [GFR] ≤ 15 mL/min/m2 body surface area [BSA]) and predicted by the investigator to need dialysis therapy within 10 weeks after the pre-screening period.
- Subjects who, as judged by the investigator, are able to comprehend the pre-defined, standardized, modality education program and have undertaken this education during the screening period.
- Subjects, or their legal representative, who, as judged by the investigator, are capable of being trained for home-based PD.
- Subjects, or their legal representative, who are able to understand and voluntarily sign an ICF.
- Subjects who are able to adhere to the study visit schedule and other protocol requirements.
- Subjects who are able to regularly visit a HD center for HD therapy (≥ 3 times per week).
- Subjects who, as judged by the investigator, are expected to remain on dialysis for at least 48 weeks.
- Subjects who have normal liver function, as judged by the investigator.
- Female subjects of childbearing potential who have a negative serum or urine pregnancy test at screening. Sexually active women of childbearing potential must agree to use adequate contraceptive methods, as judged by the investigator, while in the study.
Exclusion Criteria:
- Subjects who are HIV positive.
- Subjects who have already received a permanent PD catheter or HD access that is intended for permanent use before receiving modality education or have already received permanent dialysis. Subjects are not excluded if an access is present within 4 weeks before screening for back-up purposes or for acute treatment of life-threatening uremic symptoms, electrolyte abnormalities, or fluid overload.
- Subjects who have a serious, uncontrolled medical disorder or active infection, which, as judged by the investigator, would jeopardize their ability to receive the prescribed dialysis treatment.
- Subjects who have dementia or a mental status that would significantly affect the subject's understanding of the Informed Consent Form (ICF).
- Subjects who are pregnant, intend to become pregnant during the study period, or are breast-feeding.
- Subjects with a history of drug (defined as illicit drug use) or alcohol (defined as regular or daily consumption of more than 4 alcoholic drinks per day) abuse in the 2 years before screening.
- Subjects who have previously received renal transplantation and are still being prescribed immunosuppressive therapy.
- Subjects who are currently using or have used an investigational product within five half-lives of the physiological action or 30 days, whichever is longer, before screening.
- Subjects who are unwilling or expected to be unable to fully comply with the visits and assessments required by the protocol.
- Subjects who have previously been randomized in this study.
Subjects who are not eligible for either PD or HD, as judged by the investigator, due to:
PD: documented extensive intra-peritoneal adhesions or other condition contraindicated for PD.
HD: severe cardiac instability or other condition contraindicated for HD.
- Subjects who have a serious or acute condition that, as judged by the investigator, would preclude participation in the study.
- Subjects who have a malignancy requiring chemotherapy or radiation therapy.
- Subjects undergoing temporary dialysis treatment between the screening visit and Day 1 that is expected to exceed 6 weeks in duration.
- Subjects who have a life expectancy of less than 48 weeks.
Sites / Locations
- The First Affiliated Hospital , Sun Yet-Sen University
- Shanghai Changzheng Hospital
- Ruijin Hospital,Shanghai Jiaotong University , School of Medicine
- Huashan Hospital ,Fudan University
- Renji Hospital , Shanghai Jiaotong University , School of Medicine
- The First Affiliated Hospital , Zhejiang University, School of Medicine
- Hangzhou Hospital of Tranditional Chinese Medicine
Arms of the Study
Arm 1
Arm 2
Arm Type
Active Comparator
Experimental
Arm Label
ESRD patients receiving HD treatment
ESRD patients receiving PD treatment
Arm Description
no investigational drug involved. Only oberseve therapy treatment
no investigational drug involved. Only oberseve therapy treatment
Outcomes
Primary Outcome Measures
Assess and compare survival or all cause mortality in subjects undergoing PD or HD treatment
Secondary Outcome Measures
Assess and compare technique failure
Technique failure is defined as a change of dialysis modality (PD to HD, or HD to PD) or death. However, a temporary transfer, defined as ≤ 6 weeks duration and ≤ 2 occasions per any 52-week period, will not be considered technique failure. The use of both modalities within a 7-day period for more than 4 consecutive weeks will be considered technique failure. Technique failure will be monitored in two ways: modality failure including deaths and technique failure not including deaths.
Residual Renal Function (RRF)
RRF will be estimated if the subject's urine volume is ≥ 100 mL/24 h. RRF will be assessed by calculating GFR from a 24-h urine urea and creatinine collection and normalized to 1.73 m2 Body Surface Area. RRF will be measured at screening, visit 1 and every 12 weeks after visit 1 till the end of the study. Subjects who have a permanent modality transfer will be followed up for RRF (with the frequency of assessment determined by the modality they are switched to) until the end of the study, transplantation, stopping dialysis, lost to follow-up, or death.
Dialysis Adequacy
In subjects receiving PD, dialysis adequacy (Kt/Vurea) will be assessed at 4 weeks (visit 2), 12 weeks (visit 4) and then every 12 weeks (±14 days) until the end of the study (±14 days). Kt/Vurea target for PD patients is ≥ 1.7 per week. Kt/Vurea target for HD patients is ≥ 1.2 per dialysis session. Subjects who have a permanent modality transfer will be followed up for Kt/Vurea (with the frequency of assessment determined by the modality they are switched to) until the end of the study, transplantation, stopping dialysis, lost to follow-up, or death.
Co-morbidity Assessment
The Charlson Comorbidity Index contains 19 categories of comorbidity which are primarily defined using ICD-9-CM diagnoses codes, as well as a few procedure codes. The overall comorbidity score reflects the cumulative increased likelihood of one-year survival; the higher the score, the more severe the burden of comorbidity. Every diagnosis and procedure code is analyzed to see if it falls within one of the 16 comorbid conditions. In this study, the comorbidity assessment will be measured at visit 1, every 24 weeks (±14 days) after visit 1 to visit 23, and at the end-of-study visit.
Occurrence of Bacterial and Other Infections Infection rates
Occurrence of bacterial and other infections infection rates, especially regarding exit sites and peritoneal, will be monitored for HD and PD patients.
Hospitalization
Hospitalization rates and duration for each underlying reason will be monitored for HD and PD patients.
Transplantation Rate
Kidney transplantation is the best outcome that a patient can expect. By default, a patient will be discontinued from the study after transplantation. Imbalance of the transplantation rate between HD and PD will be assessed. However, all patients will be followed to the end of the study to assess the primary endpoint which is all-cause mortality.
Cause of Death
Cause of deaths due to acute myocardial infarction (AMI), congestive heart failure (CHF), infection (except peritonitis), peritonitis, malnutrition, stroke, cardiovascular and non-cardiovascular causes, etc., will be monitored for HD and PD patients
Change in Erythropoiesis-stimulating agent (ESA)
Dose changes in ESA dose will affect patient's status for anemia control, and will be monitored for HD and PD patients.
Change in blood pressure, hemoglobin, and S-phosphate
Blood pressure, hemoglobin, and S-phosphate will be monitored for HD and PD patients.
Subjective Global Assessment for Nutritional Status
Subjective Global Assessment (SGA) is a technique to assess a patient's nutritional status. The SGA will be measured by one dedicated, trained physician per site at visit 1, every 24 weeks (±14 days) from visit 1 to visit 23, and at the end-of-study visit.
Systemic inflammation as assessed by hs-CRP
Scores of systemic inflammation will be assessed using high-sensitivity C reactive protein (hs-CRP). Hs-CRP will be assessed at visits 1, 4-23, and at the end-of-study visit.
Quality of Life Quality of life (QOL)
Quality of Life Quality of life (QOL) will be assessed using the EQ-5D-3L (European Quality of Life - 5 Dimensions - 3L translation), the KDQoL-SF (Kidney Disease Quality of Life Short Form) questionnaires, and the Karnofsky Index. QOL will be assessed at visit 1, every 24 weeks (±14 days) from visit 1 to visit 23, and at the end-of-study visit.
Full Information
NCT ID
NCT01413074
First Posted
June 16, 2011
Last Updated
May 17, 2016
Sponsor
Baxter Healthcare Corporation
1. Study Identification
Unique Protocol Identification Number
NCT01413074
Brief Title
Survival on Peritoneal Dialysis (PD) Versus Hemodialysis (HD) in China
Official Title
A Prospective, Randomized, Multicenter, Open-Label, Interventional Study Comparing Survival in Subjects Receiving Peritoneal Dialysis vs Hemodialysis in China
Study Type
Interventional
2. Study Status
Record Verification Date
May 2016
Overall Recruitment Status
Terminated
Study Start Date
June 2011 (undefined)
Primary Completion Date
December 2013 (Actual)
Study Completion Date
December 2013 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Baxter Healthcare Corporation
4. Oversight
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
Primary Objective: The primary objective is to prospectively assess and compare survival in subjects with End Stage Renal Disease (ESRD) randomized to Peritoneal Dialysis (PD) or Hemodialysis (HD) treatment.
Secondary Objectives: The secondary objectives are to prospectively assess and compare the following parameters in subjects receiving PD or HD treatment:
Technique failure
Cause of death
Comorbidity status at baseline and changes throughout the study
Change in residual renal function (RRF)
Dialysis adequacy (i.e., Kt/Vurea)
Change in blood pressure, hemoglobin, and S-phosphate
Change in nutritional status
Occurrence of bacterial and other infections
Hospitalization, including number, duration, and underlying reason(s)
Systemic inflammation as assessed by high-sensitivity C reactive protein (hs-CRP)
Quality of life (QOL)
Safety Objectives: To compare the nature and frequency of adverse events (AEs) and serious adverse events (SAEs), including abnormal laboratory test findings with clinical significance, in subjects receiving PD or HD treatment.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
End Stage Renal Disease
Keywords
End Stage Renal Disease, ESRD, Peritoneal Dialysis, PD, Hemodialysis, HD
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
416 (Actual)
8. Arms, Groups, and Interventions
Arm Title
ESRD patients receiving HD treatment
Arm Type
Active Comparator
Arm Description
no investigational drug involved. Only oberseve therapy treatment
Arm Title
ESRD patients receiving PD treatment
Arm Type
Experimental
Arm Description
no investigational drug involved. Only oberseve therapy treatment
Intervention Type
Other
Intervention Name(s)
Peritoneal Dialysis treatment
Intervention Description
PD treatment
Intervention Type
Other
Intervention Name(s)
Hemodialysis treatment
Intervention Description
HD treatment
Primary Outcome Measure Information:
Title
Assess and compare survival or all cause mortality in subjects undergoing PD or HD treatment
Time Frame
2-5 yrs.
Secondary Outcome Measure Information:
Title
Assess and compare technique failure
Description
Technique failure is defined as a change of dialysis modality (PD to HD, or HD to PD) or death. However, a temporary transfer, defined as ≤ 6 weeks duration and ≤ 2 occasions per any 52-week period, will not be considered technique failure. The use of both modalities within a 7-day period for more than 4 consecutive weeks will be considered technique failure. Technique failure will be monitored in two ways: modality failure including deaths and technique failure not including deaths.
Time Frame
2-5 yrs.
Title
Residual Renal Function (RRF)
Description
RRF will be estimated if the subject's urine volume is ≥ 100 mL/24 h. RRF will be assessed by calculating GFR from a 24-h urine urea and creatinine collection and normalized to 1.73 m2 Body Surface Area. RRF will be measured at screening, visit 1 and every 12 weeks after visit 1 till the end of the study. Subjects who have a permanent modality transfer will be followed up for RRF (with the frequency of assessment determined by the modality they are switched to) until the end of the study, transplantation, stopping dialysis, lost to follow-up, or death.
Time Frame
2-5 yrs
Title
Dialysis Adequacy
Description
In subjects receiving PD, dialysis adequacy (Kt/Vurea) will be assessed at 4 weeks (visit 2), 12 weeks (visit 4) and then every 12 weeks (±14 days) until the end of the study (±14 days). Kt/Vurea target for PD patients is ≥ 1.7 per week. Kt/Vurea target for HD patients is ≥ 1.2 per dialysis session. Subjects who have a permanent modality transfer will be followed up for Kt/Vurea (with the frequency of assessment determined by the modality they are switched to) until the end of the study, transplantation, stopping dialysis, lost to follow-up, or death.
Time Frame
2-5 yrs.
Title
Co-morbidity Assessment
Description
The Charlson Comorbidity Index contains 19 categories of comorbidity which are primarily defined using ICD-9-CM diagnoses codes, as well as a few procedure codes. The overall comorbidity score reflects the cumulative increased likelihood of one-year survival; the higher the score, the more severe the burden of comorbidity. Every diagnosis and procedure code is analyzed to see if it falls within one of the 16 comorbid conditions. In this study, the comorbidity assessment will be measured at visit 1, every 24 weeks (±14 days) after visit 1 to visit 23, and at the end-of-study visit.
Time Frame
2-5 yrs.
Title
Occurrence of Bacterial and Other Infections Infection rates
Description
Occurrence of bacterial and other infections infection rates, especially regarding exit sites and peritoneal, will be monitored for HD and PD patients.
Time Frame
2-5 yrs.
Title
Hospitalization
Description
Hospitalization rates and duration for each underlying reason will be monitored for HD and PD patients.
Time Frame
2-5 yrs.
Title
Transplantation Rate
Description
Kidney transplantation is the best outcome that a patient can expect. By default, a patient will be discontinued from the study after transplantation. Imbalance of the transplantation rate between HD and PD will be assessed. However, all patients will be followed to the end of the study to assess the primary endpoint which is all-cause mortality.
Time Frame
2-5 yrs.
Title
Cause of Death
Description
Cause of deaths due to acute myocardial infarction (AMI), congestive heart failure (CHF), infection (except peritonitis), peritonitis, malnutrition, stroke, cardiovascular and non-cardiovascular causes, etc., will be monitored for HD and PD patients
Time Frame
2-5 yrs.
Title
Change in Erythropoiesis-stimulating agent (ESA)
Description
Dose changes in ESA dose will affect patient's status for anemia control, and will be monitored for HD and PD patients.
Time Frame
2-5 yrs.
Title
Change in blood pressure, hemoglobin, and S-phosphate
Description
Blood pressure, hemoglobin, and S-phosphate will be monitored for HD and PD patients.
Time Frame
2-5 yrs.
Title
Subjective Global Assessment for Nutritional Status
Description
Subjective Global Assessment (SGA) is a technique to assess a patient's nutritional status. The SGA will be measured by one dedicated, trained physician per site at visit 1, every 24 weeks (±14 days) from visit 1 to visit 23, and at the end-of-study visit.
Time Frame
2-5 yrs.
Title
Systemic inflammation as assessed by hs-CRP
Description
Scores of systemic inflammation will be assessed using high-sensitivity C reactive protein (hs-CRP). Hs-CRP will be assessed at visits 1, 4-23, and at the end-of-study visit.
Time Frame
2-5 yrs.
Title
Quality of Life Quality of life (QOL)
Description
Quality of Life Quality of life (QOL) will be assessed using the EQ-5D-3L (European Quality of Life - 5 Dimensions - 3L translation), the KDQoL-SF (Kidney Disease Quality of Life Short Form) questionnaires, and the Karnofsky Index. QOL will be assessed at visit 1, every 24 weeks (±14 days) from visit 1 to visit 23, and at the end-of-study visit.
Time Frame
2-5 yrs.
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Subjects of either sex, aged 18 years or older at time of randomization.
Subjects diagnosed with ESRD (glomerular filtration rate [GFR] ≤ 15 mL/min/m2 body surface area [BSA]) and predicted by the investigator to need dialysis therapy within 10 weeks after the pre-screening period.
Subjects who, as judged by the investigator, are able to comprehend the pre-defined, standardized, modality education program and have undertaken this education during the screening period.
Subjects, or their legal representative, who, as judged by the investigator, are capable of being trained for home-based PD.
Subjects, or their legal representative, who are able to understand and voluntarily sign an ICF.
Subjects who are able to adhere to the study visit schedule and other protocol requirements.
Subjects who are able to regularly visit a HD center for HD therapy (≥ 3 times per week).
Subjects who, as judged by the investigator, are expected to remain on dialysis for at least 48 weeks.
Subjects who have normal liver function, as judged by the investigator.
Female subjects of childbearing potential who have a negative serum or urine pregnancy test at screening. Sexually active women of childbearing potential must agree to use adequate contraceptive methods, as judged by the investigator, while in the study.
Exclusion Criteria:
Subjects who are HIV positive.
Subjects who have already received a permanent PD catheter or HD access that is intended for permanent use before receiving modality education or have already received permanent dialysis. Subjects are not excluded if an access is present within 4 weeks before screening for back-up purposes or for acute treatment of life-threatening uremic symptoms, electrolyte abnormalities, or fluid overload.
Subjects who have a serious, uncontrolled medical disorder or active infection, which, as judged by the investigator, would jeopardize their ability to receive the prescribed dialysis treatment.
Subjects who have dementia or a mental status that would significantly affect the subject's understanding of the Informed Consent Form (ICF).
Subjects who are pregnant, intend to become pregnant during the study period, or are breast-feeding.
Subjects with a history of drug (defined as illicit drug use) or alcohol (defined as regular or daily consumption of more than 4 alcoholic drinks per day) abuse in the 2 years before screening.
Subjects who have previously received renal transplantation and are still being prescribed immunosuppressive therapy.
Subjects who are currently using or have used an investigational product within five half-lives of the physiological action or 30 days, whichever is longer, before screening.
Subjects who are unwilling or expected to be unable to fully comply with the visits and assessments required by the protocol.
Subjects who have previously been randomized in this study.
Subjects who are not eligible for either PD or HD, as judged by the investigator, due to:
PD: documented extensive intra-peritoneal adhesions or other condition contraindicated for PD.
HD: severe cardiac instability or other condition contraindicated for HD.
Subjects who have a serious or acute condition that, as judged by the investigator, would preclude participation in the study.
Subjects who have a malignancy requiring chemotherapy or radiation therapy.
Subjects undergoing temporary dialysis treatment between the screening visit and Day 1 that is expected to exceed 6 weeks in duration.
Subjects who have a life expectancy of less than 48 weeks.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Quian Jia-Qi, Prof.
Organizational Affiliation
Shanghai Jiao Tong University School of Medicine
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Yu Xue-qing, Prof.
Organizational Affiliation
First Affiliated Hospital, Sun Yat-Sen University
Official's Role
Principal Investigator
Facility Information:
Facility Name
The First Affiliated Hospital , Sun Yet-Sen University
City
Guangzhou
State/Province
Guangdong
ZIP/Postal Code
510080
Country
China
Facility Name
Shanghai Changzheng Hospital
City
Shanghai
State/Province
Shanghai
ZIP/Postal Code
200003
Country
China
Facility Name
Ruijin Hospital,Shanghai Jiaotong University , School of Medicine
City
Shanghai
State/Province
Shanghai
ZIP/Postal Code
200025
Country
China
Facility Name
Huashan Hospital ,Fudan University
City
Shanghai
State/Province
Shanghai
ZIP/Postal Code
200040
Country
China
Facility Name
Renji Hospital , Shanghai Jiaotong University , School of Medicine
City
Shanghai
State/Province
Shanghai
Country
China
Facility Name
The First Affiliated Hospital , Zhejiang University, School of Medicine
City
Hangzhou
State/Province
Zhejiang
ZIP/Postal Code
310003
Country
China
Facility Name
Hangzhou Hospital of Tranditional Chinese Medicine
City
Hangzhou
State/Province
Zhejiang
ZIP/Postal Code
310007
Country
China
12. IPD Sharing Statement
Learn more about this trial
Survival on Peritoneal Dialysis (PD) Versus Hemodialysis (HD) in China
We'll reach out to this number within 24 hrs